Iqvia Holdings Stock Fair Value Calculator – IQVIA HOLDINGS Reports Strong Q2 Earnings for 2023

August 21, 2023

☀️Earnings Overview

IQVIA HOLDINGS ($NYSE:IQV) reported a total revenue of USD 3728.0 million for the quarter ended June 30 2023, which was 5.3% higher than the same quarter in the previous year. Net income for the period was also significantly up by 16.0%, with a total of USD 297.0 million. The figures were reported on August 1 2023.

Price History

IQVIA HOLDINGS, formerly known as Quintiles IMS Holdings Inc., reported strong second quarter earnings for 2023. On Tuesday, IQVIA HOLDINGS stock opened at $220.6 and closed at $219.1, down by 2.1% from the previous closing price of 223.8. The company attributed its strong performance to strong organic growth across all its major businesses – analytics, contract research and technology solutions. This was further bolstered by the addition of new customers and expansion of existing customer relationships.

In addition, IQVIA HOLDINGS’ investments in new technologies and services have also helped the company deliver strong returns in the quarter. Overall, IQVIA HOLDINGS reported a strong second quarter, despite its share price dropping by 2.1%. With its investments in new technologies and services, the company looks set to continue its strong performance in the quarters to come. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Iqvia Holdings. More…

    Total Revenues Net Income Net Margin
    14.68k 1.1k 7.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Iqvia Holdings. More…

    Operations Investing Financing
    2.24k -2.01k -262
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Iqvia Holdings. More…

    Total Assets Total Liabilities Book Value Per Share
    26.04k 20.29k 31.39
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Iqvia Holdings are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    10.3% 39.2% 13.1%
    FCF Margin ROE ROA
    10.8% 20.5% 4.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Iqvia Holdings Stock Fair Value Calculator

    At GoodWhale, we recently conducted an analysis of IQVIA HOLDINGS‘ wellbeing. Through our proprietary Valuation Line, we have calculated the fair value of IQVIA HOLDINGS share to be around $240.9. However, we have noticed that the share is currently being traded at $219.1, which is a fair price that is undervalued by 9.0%. We believe this presents a great buying opportunity for investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    IQVIA Holdings Inc is a provider of data, technology, and analytical solutions to the healthcare industry. The company’s competitors include Diaceutics PLC, Centogene NV, and CMIC HOLDINGS Co Ltd.

    – Diaceutics PLC ($LSE:DXRX)

    Diaceutics is a diagnostic company that develops and commercializes diagnostic tests for personalized medicine. The company has a market cap of 69.27M as of 2022 and a return on equity of 0.03%. The company’s products are used by pharmaceutical companies to guide the development and use of personalized medicines.

    – Centogene NV ($NASDAQ:CNTG)

    As of 2022, Centogene NV has a market cap of 28.44M and a return on equity of -141.43%. The company is a genetic testing and precision medicine company that uses its proprietary technology platform to provide insights into the cause and progression of rare and complex diseases. The company’s products and services are used by pharmaceutical and biotech companies, academic research institutes, and patients and their families to improve the understanding of disease and enable the development of personalized treatments.

    – CMIC HOLDINGS Co Ltd ($TSE:2309)

    CMIC Holdings Co Ltd is a Japanese conglomerate with a market capitalization of 29.85 billion as of 2022. The company has a return on equity of 22.28%. CMIC Holdings Co Ltd is involved in a wide range of businesses, including chemicals, pharmaceuticals, food, and beverages.


    IQVIA HOLDINGS has seen strong performance in its recent financial quarter, with total revenue increasing by 5.3% year-on-year and net income rising 16.0%. This has been a positive result for investors, and analysts are optimistic about the company’s prospects going forward. With a diversified portfolio of products and services, including data and analytics, technology solutions, and consulting, IQVIA HOLDINGS is well positioned to continue to drive growth in the coming years. Investors should review the latest financials for further insight into the company’s performance.

    Recent Posts

    Leave a Comment